We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


19 November 2003 By Robert Cyran

The Swiss pharmaceutical company unveiled positive results from four clinical trials in its annual R&D day. With an enormously fat pipeline and few drugs under generic threat, Novartis looks set for years of above average growth.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)